about
Vancomycin-Induced Thrombocytopenia: A Narrative Review.Accidental and iatrogenic causes of acute kidney injury.The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunctionOptimization of time to initial vancomycin target trough improves clinical outcomesThree-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort studyVancomycin dosing in patients on intermittent hemodialysis.Vancomycin dosing and monitoring 2 years after the guidelines.Infectious complications in dialysis--epidemiology and outcomes.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia.Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies.Vancomycin: the tale of the vanquisher and the pyrrhic victory.A SILAC-Based Approach Elicits the Proteomic Responses to Vancomycin-Associated Nephrotoxicity in Human Proximal Tubule Epithelial HK-2 Cells.Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing HemodialysisA specially tailored vancomycin continuous infusion regimen for renally impaired critically ill patients.Clinical analysis of pulmonary infection in hemodialysis patients.Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients.Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure.Medical safety in the care of the person with end-stage kidney disease.
P2860
Q33436796-90058149-50F3-4712-938F-C54CB60D7218Q33954859-D6A644B6-6B61-4163-BD14-E12EC160D0F3Q35524820-B3FEE9C9-26F6-453B-9AE8-C782310D7489Q35676081-FA02F3F6-091C-41DF-9E28-B7D538306A58Q35862844-C9590C31-13EA-425C-8062-F1F043162CDDQ35914849-66BE50D4-E2C9-4ACF-A79C-8360718A3531Q36200911-6FAAD782-8D40-4569-9670-2DC433ECE49FQ36454724-64AAC50C-FAC8-4B33-8DB0-D773181B181EQ37845424-20EBF26F-8CD5-4893-A206-71B9A0A83CA9Q37892556-F4AC246C-37FD-447B-986F-BA4212FEFD66Q37969996-70BF4B91-F7F5-4E12-BE96-B949CB4D01BBQ37992997-84135726-2323-4012-97A3-B3B276ED7F5DQ38068293-D4750A1C-7C54-4D96-81F6-3733AF8934DBQ38157572-D1DB2561-4A85-4B15-943E-61B9E3BA849BQ38285837-8A81B6F6-E9C7-46E7-957C-F28E6F899E79Q38542797-FCFC9AD0-6670-44B5-93AA-2DEC584FA367Q38797022-7472F473-0797-497F-82CD-DADEE506F56CQ39203427-E6A9A860-E10E-4791-955A-C3F3770AFCACQ40104555-F92A4F75-107C-4EF2-B8F4-E2A8B5C40F0EQ40240848-008F66E9-0930-415B-BA36-838B4247B8C7Q40499611-E5F614FA-62E7-4CF0-B087-B6D5751B06ACQ41103109-CA7A620F-B319-456D-8674-135072AFB9D5Q50119222-C201B292-A3C2-4995-B98E-7801F367ABBB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent changes in vancomycin use in renal failure.
@en
Recent changes in vancomycin use in renal failure.
@nl
type
label
Recent changes in vancomycin use in renal failure.
@en
Recent changes in vancomycin use in renal failure.
@nl
prefLabel
Recent changes in vancomycin use in renal failure.
@en
Recent changes in vancomycin use in renal failure.
@nl
P356
P1433
P1476
Recent changes in vancomycin use in renal failure.
@en
P2093
An S De Vriese
Stefaan J Vandecasteele
P2888
P304
P356
10.1038/KI.2010.35
P407
P577
2010-02-24T00:00:00Z